Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 120% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- Strong ROE of 38.9% with 15.1% net margin
- High dividend yield of 4.2%
BRISTOL-MYERS SQUIBB COMPANY (BMY) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $120.3 billion . Key value metrics: P/E ratio 16.8, P/B ratio 6.51, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BRISTOL-MYERS SQUIBB COMPANY — Fundamental Analysis Summary
BRISTOL-MYERS SQUIBB COMPANY (BMY) is currently trading 120% above its Graham Number of $26.82, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 16.8x.
On financial health, BMY shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 38.9% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 2.55.
StockPik's composite Value Score for BMY is 76/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BMY shows revenue declining at 0% year-over-year, with earnings growing at 179%.
BMY pays a solid dividend yield of 4.2%.